Affiliation:
1. Division of Hematology, Massachusetts General Hospital, Harvard Medical School, Boston, MA
Abstract
Abstract
Hereditary hemorrhagic telangiectasia (HHT) management is evolving because of the emergence and development of antiangiogenic therapies to eliminate bleeding telangiectasias and achieve hemostasis. This progress is reflected in recent clinical recommendations published in the Second International Guidelines for the Diagnosis and Treatment of HHT, in which systemic therapies including antiangiogenics and antifibrinolytics are now recommended as standard treatment options for bleeding. This review highlights the new recommendations especially relevant to hematologists in managing bleeding, anticoagulation, and anemia in patients with HHT.
Publisher
American Society of Hematology
Subject
Cell Biology,Hematology,Immunology,Biochemistry
Reference80 articles.
1. Epistaxis as an indication of impaired nutrition and of degeneration of the vascular system;Sutton;Med Mirror,1864
2. Épistaxis répétées chez un sujet porteur de petits angiomes cutanés et muqueux [Repeated epistaxis in a subject with small skin and mucous angiomas];Rendu;Bull Mem Soc Med Hop Paris,1896
3. Vascular endothelial growth factor is a secreted angiogenic mitogen;Leung;Science,1989
4. Pituitary follicular cells secrete a novel heparin-binding growth factor specific for vascular endothelial cells;Ferrara;Biochem Biophys Res Commun,1989
5. Vascular endothelial growth factor serum levels are elevated in patients with hereditary hemorrhagic telangiectasia;Cirulli;Acta Haematol,2003
Cited by
52 articles.
订阅此论文施引文献
订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献